Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
暂无分享，去创建一个
A. Brandes | L. Gianni | P. Morandi | F. Montemurro | M. Zambetti | S. Gori | C. Bengala | C. Zamagni | G. Bisagni | A. Stell | K. Cagossi | C. Iannacone